Quarterly report
Open the filing on sec.gov
Tilray Brands, Inc. (TLRY)
Nasdaq: TLRY · Medicinal Chemicals & Botanical Products · New York, NY · filing with the SEC since 2018
The companyfiscal 2026, as filed
Revenue$915M+11.5%
Net income-$121M+94.4%
Earnings per share$-1.09+95.6%
Operating cash flow-$69.1M+26.9%
Cash$226M+1.9%
Debtn/a
Shareholders’ equity$1.61B+6.8%
Shares, diluted111.8M+25.6%
Return on equity-7.5%
The recordfrom its filings
Filings in 202648
Newest filingOct 8 · 10-Q
Annual reportJul 28, 2026
Quarterly reportOct 8, 2026
Next report due10-Q by Jan 9
Insider sales, 12 months$200,000
Insider buys, 12 months$100,000
Patents granted0
Filer categoryLarge accelerated filer
Trailing twelve months to Aug 2026Revenue $963MNet income -$164MCash from operations -$84.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.